Summary

Europe 3D Bioprinting in Medical Market is valued approximately USD 360 million in 2023 and is anticipated to grow with a healthy growth rate of more than 17.18% over the forecast period 2024-2032. 3D bioprinting in the medical realm represents a groundbreaking approach to tissue engineering and regenerative medicine. It entails the precise layer-by-layer deposition of biomaterials, cells, and growth factors to fabricate three-dimensional structures mirroring the intricate architecture and functionality of natural tissues and organs. This state-of-the-art technology holds tremendous potential for diverse applications, ranging from organ transplantation and drug screening to disease modeling and personalized medicine. Moreover, the versatility of 3D bioprinting extends beyond tissue engineering, encompassing a spectrum of medical and pharmaceutical applications, including drug screening, disease modeling, and personalized medicine.

Healthcare institutions in Europe are increasingly adopting 3D bioprinting technologies for research, clinical applications, and medical education. Bioprinted tissues and organs are used for drug screening, disease modeling, surgical planning and personalized medicine, driving market demand in the region. Regulatory agencies in Europe are establishing clear guidelines and standards for the approval and commercialization of 3D bioprinted medical products. Regulatory support ensures safety, efficacy and quality control of bioprinted tissues and organs, fostering market growth and investment in the region. Furthermore, Europe 3D Bioprinting in Medical Market is driven by Rising Demand for Regenerative Medicine and Increasing investment in Research and Development. However, high development costs is expected to stifle market growth between 2022 and 2032.

The key countries considered for the Europe 3D Bioprinting in Medical market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany held the largest market in the regional market. Germany has a strong tradition of excellence in engineering, biotechnology and medical research, providing a solid foundation for the development and commercialization of 3D bioprinting technologies. The country boasts world-class research institutions, universities, and industry clusters dedicated to advancing bioprinting techniques and applications. Additionally, Germany benefits from substantial public and private investment in research and development, fostering innovation and technology transfer in the bioprinting sector. On the other hand, the market in UK is expected to develop at the fastest rate over the forecast period.

Major market player included in this report are:
Regemat 3D
Fluicell AB
Ourobotics Bioprinting
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Products and Solution
Bioprinters
Consumables and accessories
Software and services

By Technology
Extrusion based bioprinting
Inkjet based bioprinting
Laser assisted bioprinting
Others

By Application
Tissue engineering and regenerative medicine
Drug discovery and development
Others

By End User
Biotechnology and pharmaceutical companies
Academic and research institutes
Others



By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Europe 3D Bioprinting in Medical Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Europe 3D Bioprinting in Medical Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Products and Solutions
2.3.2. By Technology
2.3.3. By Application
2.3.4. By End User
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Europe 3D Bioprinting in Medical Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Europe 3D Bioprinting in Medical Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Europe 3D Bioprinting in Medical Market Size & Forecasts by Products and Solutions 2022-2032
5.1. Bioprinters
5.2. Consumables and accessories
5.3. Software and services
Chapter 6. Europe 3D Bioprinting in Medical Market Size & Forecasts by Technology 2022-2032
6.1. Extrusion based bioprinting
6.2. Inkjet based bioprinting
6.3. Laser assisted bioprinting
6.4. Others
Chapter 7. Europe 3D Bioprinting in Medical Market Size & Forecasts by Application 2022-2032
7.1. Tissue engineering and regenerative medicine
7.2. Drug discovery and development
7.3. Others
Chapter 8. Europe 3D Bioprinting in Medical Market Size & Forecasts by End User 2022-2032
8.1. Biotechnology and pharmaceutical companies
8.2. Academic and research institutes
8.3. Others
Chapter 9. Europe 3D Bioprinting in Medical Market Size & Forecasts by Country 2022-2032
9.1. U.K. 3D Bioprinting in Medical Market
9.1.1.1. Products and Solution breakdown size & forecasts, 2022-2032
9.1.1.2. Technology breakdown size & forecasts, 2022-2032
9.1.1.3. Application breakdown size & forecasts, 2022-2032
9.1.1.4. End User breakdown size & forecasts, 2022-2032
9.2. Germany 3D Bioprinting in Medical Market
9.3. France 3D Bioprinting in Medical Market
9.4. Spain 3D Bioprinting in Medical Market
9.5. Italy 3D Bioprinting in Medical Market
9.6. Rest of Europe 3D Bioprinting in Medical Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Company 1
10.1.2. Company 2
10.1.3. Company 3
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Regemat 3D
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Fluicell AB
10.3.3. Ourobotics Bioprinting
10.3.4. Company 4
10.3.5. Company 5
10.3.6. Company 6
10.3.7. Company 7
10.3.8. Company 8
10.3.9. Company 9
10.3.10. Company 10
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes